329 related articles for article (PubMed ID: 28501249)
41. Features of Late Recurrence Following Transanal Local Excision for Early Rectal Cancer.
Oh BY; Yun HR; Kim SH; Yun SH; Kim HC; Lee WY; Chun HK; Cho YB
Dis Colon Rectum; 2015 Nov; 58(11):1041-7. PubMed ID: 26445176
[TBL] [Abstract][Full Text] [Related]
42. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.
Marinello FG; Frasson M; Baguena G; Flor-Lorente B; Cervantes A; Roselló S; Espí A; García-Granero E
Dis Colon Rectum; 2015 Jun; 58(6):556-65. PubMed ID: 25944427
[TBL] [Abstract][Full Text] [Related]
43. Robotic versus open total mesorectal excision for rectal cancer: comparative study of short and long-term outcomes.
Ghezzi TL; Luca F; Valvo M; Corleta OC; Zuccaro M; Cenciarelli S; Biffi R
Eur J Surg Oncol; 2014 Sep; 40(9):1072-9. PubMed ID: 24646748
[TBL] [Abstract][Full Text] [Related]
44. Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
Habr-Gama A; Lynn PB; Jorge JM; São Julião GP; Proscurshim I; Gama-Rodrigues J; Fernandez LM; Perez RO
Dis Colon Rectum; 2016 Apr; 59(4):264-9. PubMed ID: 26953984
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for early complications after laparoscopic total mesorectal excision for locally advanced rectal cancer: A single center experience.
Liu L; Wang T; Zhang G; Dai R; Liang H; Tang L
J Cancer Res Ther; 2016; 12(1):350-4. PubMed ID: 27072262
[TBL] [Abstract][Full Text] [Related]
46. Can less be more? Organ preservation strategies in the management of rectal cancer.
Rouleau-Fournier F; Brown CJ
Curr Oncol; 2019 Nov; 26(Suppl 1):S16-S23. PubMed ID: 31819706
[TBL] [Abstract][Full Text] [Related]
47. [Organ preserving strategies for rectal cancer treatment].
Vendrely V; Denost Q; Amestoy F; Célérier B; Smith D; Rullier A; Rullier É
Cancer Radiother; 2015 Oct; 19(6-7):404-9. PubMed ID: 26278990
[TBL] [Abstract][Full Text] [Related]
48. Laparoscopic intersphincteric resection for low rectal cancer.
Orsenigo E; Di Palo S; Vignali A; Staudacher C
Surg Oncol; 2007 Dec; 16 Suppl 1():S117-20. PubMed ID: 18023571
[TBL] [Abstract][Full Text] [Related]
49. Local excision for rectal carcinoma.
Kim E; Hwang JM; Garcia-Aguilar J
Clin Colorectal Cancer; 2008 Nov; 7(6):376-85. PubMed ID: 19036690
[TBL] [Abstract][Full Text] [Related]
50. ASO Author Reflections: Local Excision Following Neoadjuvant Therapy for Rectal Cancer: A Compromise Between TME and Watch-and-Wait in Patients with Major Response.
Bao QR; Capelli G; Spolverato G; Pucciarelli S
Ann Surg Oncol; 2021 May; 28(5):2809-2810. PubMed ID: 33095361
[No Abstract] [Full Text] [Related]
51. [Effect of total mesorectal excision and preoperative chemoradiotherapy on local recurrence in rectal cancer].
Wu AW; Gu J; Wang J
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 May; 9(3):207-9. PubMed ID: 16721678
[TBL] [Abstract][Full Text] [Related]
52. Local excision for early rectal cancer in the era of neoadjuvant strategies.
Tepetes K; Spyridakis ME
Hepatogastroenterology; 2007 Sep; 54(78):1689-93. PubMed ID: 18019696
[TBL] [Abstract][Full Text] [Related]
53. Factors affecting the difficulty of laparoscopic total mesorectal excision with double stapling technique anastomosis for low rectal cancer.
Akiyoshi T; Kuroyanagi H; Oya M; Konishi T; Fukuda M; Fujimoto Y; Ueno M; Miyata S; Yamaguchi T
Surgery; 2009 Sep; 146(3):483-9. PubMed ID: 19715805
[TBL] [Abstract][Full Text] [Related]
54. [What's new in rectal cancer?].
Ben Abid S; Hefaiedh R; Mzoughi Z; Miloudi N; Naafa A; Khalfallah MT
Tunis Med; 2014 Oct; 92(10):593-600. PubMed ID: 25860672
[TBL] [Abstract][Full Text] [Related]
55. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy?
Hughes R; Harrison M; Glynne-Jones R
Acta Oncol; 2010 Apr; 49(3):378-81. PubMed ID: 20151936
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
57. Treatment of locally advanced rectal cancer.
Klaassen RA; Nieuwenhuijzen GA; Martijn H; Rutten HJ; Hospers GA; Wiggers T
Surg Oncol; 2004; 13(2-3):137-47. PubMed ID: 15572096
[TBL] [Abstract][Full Text] [Related]
58. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
Madbouly KM; Hussein AM; Abdelzaher E
Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
[TBL] [Abstract][Full Text] [Related]
59. Local excision of rectal tumours by minimally invasive transanal surgery.
Hershman MJ; Mohammad H; Hussain A; Ahmed A
Br J Hosp Med (Lond); 2013 Jul; 74(7):387-90. PubMed ID: 24159640
[No Abstract] [Full Text] [Related]
60. New trends in neoadjuvant therapy of locally advanced rectal cancer from a surgeons perspective - a commentary.
Kala Z; Zatloukal M; Čan V; Hemmelová B; Ostřížková L; Bohatá Š; Slabý O; Svoboda M; Šlampa P
Klin Onkol; 2020; 33(5):362-371. PubMed ID: 33108881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
